Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström MacroglobulinemiaSteven P. Treon, Jorge J. Castillo, Joshua Gustine et al.|Journal of Clinical Oncology|2018Cited by 176
Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment StrategiesSteven P. Treon, Jorge J. Castillo, Gloria Chan et al.|Journal of Clinical Oncology|2020Cited by 165
Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemiaLian Xu, Steven P. Treon, Nicholas Tsakmaklis et al.|Blood|2017Cited by 138
<i><scp>MYD</scp>88</i> wild‐type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survivalSteven P. Treon, Jorge J. Castillo, Joshua Gustine et al.|British Journal of Haematology|2017Cited by 105
<i>CXCR4</i> mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinibJorge J. Castillo, Steven P. Treon, Lian Xu et al.|British Journal of Haematology|2019Cited by 103